PDF下载 ( 132 KB)
The efficacy of HBeAg-positive chronic hepatitis B with Adefovir dipivoxil and Ganluoxin pills in 24 weeks
-
摘要: 目的为评价阿德福韦酯联合肝纤欣丸治疗HBeAg阳性慢性乙型肝炎患者24周的疗效。方法对52例HBeAg阳性慢性乙型肝炎患者分别给予阿德福韦酯联合肝络欣丸治疗和阿德福韦酯单药治疗,观察治疗24周期间,在第16周、24周末肝功能中的丙氨酸氨基转移酶(ALT)、HBV DNA变化。结果阿德福韦酯和肝络欣丸联合应用在降低HBV DNA和ALT水平,提高HBV DNA转阴率、ALT复常率方面疗效均优于单用阿德福韦酯。结论阿德福韦酯和肝络欣联用疗效优于单用阿德福韦酯。Abstract: Objective To evaluate the efficacy of HBeAg-positive chronic hepatitis B with Adefovir dipivoxil and Ganluoxin pills in 24 weeks.Methods 52 patients with HBeAg-positive chronic hepatitis B were treated with Adefovir dipivoxil and Ganluoxin pills or Adefovir dipivoxil alone.In this 24 weeks, we mostly observed the change of the level of ALT and HBV DNA at the end of 16th and 24th week.Results The efficacy of the patients with HBeAg-positive chronic hepatitis B who were treated with Adefovir dipivoxil and Ganluoxin is higher than those were treated with Adefovir dipivoxil alone in the decrease of ALT and HBV DNA, and in the increase of the negative rate of HBV DNA and the recovery rate of ALT.Conclusion The efficacy of Adefovir dipivoxil and Ganluoxin pills is higher than that of adefovir dipivoxil alone.
-
Key words:
- Adefovir dipivoxil /
- Ganluoxin pills /
- HBeAg /
- efficacy
-
为使作者了解我刊的编辑出版计划，及时地为我刊惠赐稿件，《临床肝胆病杂志》编委会确定了2022年1-10期“重点号”选题及各期执行主编：
1期 大数据与人工智能赋能肝脏外科数字诊疗新时代····························································刘景丰
2期 儿童肝衰竭的诊断与治疗····························································王建设
3期 肝癌精准诊疗新进展····························································陈 磊
4期 自身免疫性肝病——识机制进展，促临床提升····························································闫惠平
5期 免疫治疗新时代下肝胆肿瘤治疗新进展····························································周 俭
6期 肝硬化门静脉高压的进展与挑战····························································陈金军
7期 非肝硬化性门静脉高压研究进展····························································徐小元
8期 从基础的视角看慢性乙型肝炎治愈及在研新药临床试验评价····························································鲁凤民
9期 肝硬化及其主要合并症的中西医结合治疗····························································刘 平
10期 期异种肝移植的发展与创新····························································窦科峰
为本刊重点号的投稿请注明“***重点号投稿”字样。
对于围绕重点号选题的文章，本刊将择优优先发表。欢迎广大作者踊跃投稿。
《临床肝胆病杂志》编辑部
2022年3月20日
-
[1]中华医学会.病毒性防治方案[J].中华传染病杂志, 2001, 19∶56-62. [2]Wolters LM, Niesters HG, de Man RA, et al.Nucleoside analoguesfor chronic hepatitis B[J].Eur J Gastroenterol Hepatol, 2001, 13 (12) ∶1499-1506. [3]蒋晔, 徐智儒, 张晓青.抗乙肝新药阿德福韦酯的研究进展[J].中国新药与临床杂志, 2004, 23 (6) ∶373-377. [4]Hadziyannis SJ, Tassopoulos NS, Heathcote EJ, et al.Adefovir dip-ivoxil for the treatment of hepatitis B e antigen-negative chronichepatitis B[J].N Engl J Med, 2003, 348∶800-807. [5]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for hetreatment of hepatitis B e antigen-positive chronic hepatitis B[J].NEngl J Med, 2003, 348∶808-816. [6]Hadziyannis S, Tassopoulos N, Chang TT, et al.Three-year studyof adefovir dipivoxil (ADV) demonstrates sustained efficacy in pre-sumed precore mutant chronic hepatitis B patients in a long-termsafety and efficacy study[J].J Hepatol, 2004 (Suppl 1) ∶17 (Ab-stract 46) . [7]赵钢, 陈建杰.王灵台教授论补肾法为主治疗慢性乙型肝炎的机制[J].中国中西医结合杂志, 2005, 25 (1) ∶78-79. [8]高月球, 王灵台, 陈建杰.补肾冲剂治疗慢性乙型肝炎的临床研究[J].上海中医药大学学报, 2001, 15 (1) ∶34. [9]谷强业, 陈合明.拉米夫定加肝络欣治疗慢性乙型肝炎疗效及对YMDD变异的影响[J].临床肝胆病杂志, 2005, 21 (2) ∶80. -
下载:
